Many countries are now developing elimination strategies, but there is little understanding of what is required to achieve these goals. Myanmar has set national HCV targets to achieve 50 per cent of people diagnosed and 50 per cent treated by 2030.
Alfred Ethics approval on 15 June 2018
Myanmar IRB submission on 21 Mar 2019
Alfred Ethics approval on amendment on 7 May 2019
Myanmar IRB review meeting on 27 August 2019
Myanmar IRB resubmission of amendments on 1 November 2019 Myanmar IRB approval on 27 December 2019
This project used mathematical modelling to estimate the national treatment scale-up required to reach the HCV elimination targets by 2030 and to determine the expected budget impact and return on investment over time of the optimal screening and treatment strategy.
Funding
Partners
- Gilead Sciences Inc.
Partners +
Collaborators
- National Hepatitis Control Program
Project
Team
Meet the project team. Together, we are translating research into better health, for all.
